Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sab Biotherapeutics Inc
(NQ:
SABS
)
2.870
-0.060 (-2.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,965
Open
2.800
Bid (Size)
2.700 (1)
Ask (Size)
2.950 (20)
Prev. Close
2.930
Today's Range
2.800 - 2.900
52wk Range
0.4100 - 6.390
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
SAb Biotherapeutics Rebrands as SAB BIO
June 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+310.00%
+310.00%
1 Month
+5.09%
+5.09%
3 Month
-33.87%
-33.87%
6 Month
-50.69%
-50.69%
1 Year
+272.73%
+272.73%
More News
Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 18, 2024
Via
Benzinga
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
June 18, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
May 23, 2024
Via
Benzinga
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
May 21, 2024
Via
InvestorPlace
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
May 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
March 25, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
February 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Via
Benzinga
Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday
January 03, 2024
Via
Benzinga
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying
December 01, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
November 29, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia
November 29, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.